Elevance Health news
The WiseView Research desk's stories that name Elevance Health, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The ELV page →
- HeadlineImplied Volatility Surging for Elevance Health Stock Options
- HeadlineElevance Health: Better Results, But Not Enough To Buy
- HeadlineElevance: 3 Key Takeaways for Long-Term Investors
- HeadlineElevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run?
- HeadlineElevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript
- HeadlineELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook
- HeadlineWhat Elevance Health (ELV) Said on Its Q3 Earnings Call
- HeadlineCompared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics
- HeadlineElevance Health (ELV) Surpasses Q3 Earnings and Revenue Estimates
- HeadlineElevance Health Names Jeff Park President of Carelon
- HeadlineElevance Health Raises Yearly Outlook as Profit, Revenue Rise
- HeadlineElevance lifts 2026 profit forecast on better medical cost management
- HeadlineElevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
- HeadlineUnveiling Elevance Health (ELV) Q3 Outlook: Wall Street Estimates for Key Metrics
- HeadlineElevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results?
- HeadlineElevance Health's Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
- CongressMarkwayne Mullin bought $15,001 - $50,000 of ELV
- CongressJohn Fetterman sold $1,001 - $15,000 of ELV
- CongressRo Khanna bought $1,001 - $15,000 of ELV
- CongressRo Khanna bought $1,001 - $15,000 of ELV
- CongressLisa McClain sold $1,001 - $15,000 of ELV
- CongressGilbert Cisneros bought $1,001 - $15,000 of ELV
- CongressRo Khanna bought $1,001 - $15,000 of ELV
- CongressLisa McClain bought $1,001 - $15,000 of ELV
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.